Conference
Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized Trial
Abstract
PURPOSE: The phase 2 randomized study SABR-COMET demonstrated that in patients with controlled primary tumors and 1 to 5 oligometastatic lesions, SABR was associated with improved progression-free survival (PFS) compared with standard of care (SoC), but with higher costs and treatment-related toxicities. The aim of this study was to assess the cost-effectiveness of SABR versus SoC in this setting.
METHODS AND MATERIALS: A Markov model was …
Authors
Qu XM; Chen Y; Zaric GS; Senan S; Olson RA; Harrow S; John-Baptiste A; Gaede S; Mulroy LA; Schellenberg D
Volume
109
Pagination
pp. 1176-1184
Publisher
Elsevier
Publication Date
April 2021
DOI
10.1016/j.ijrobp.2020.12.001
Conference proceedings
International Journal of Radiation Oncology • Biology • Physics
Issue
5
ISSN
0360-3016